Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro- α silencing and antitumor activity against ovarian cancer.
In conclusion, gro-α shRNA-loaded nanoparticles conjugated with FSH peptides overcame the drawbacks of the in vivo application of RNAi therapeutics and polymer-based nanocarriers and showed safe antitumor efficacy. Our study might contribute to the application of FSHR-based targeted therapy and imaging in cancer.
PMID: 29461120 [PubMed - as supplied by publisher]
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Genetics | Hormones | Nanotechnology | Ovarian Cancer | Ovaries | Polyethylene Glycol | Study | Toxicology